Mindfulness for paranoia

Completed

• Conditions: Specialty: Mental Health, Primary sub-specialty: Psychosis - schizophrenia; Schizophrenia; UKCRC code/ Disease: Mental Health/ Schizophrenia, schizotypal and delusional disorders; Mental and Behavioural Disorders

• Registration Number: ISRCTN17852603
• Lead Sponsor: Surrey and Borders Partnership NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-03
• Last Update Posted: 18 June 2018
• Study Completion: 2018-11-30

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Diagnosis of schizophrenia, and be experiencing current distressing persecutory delusions (assessed using the PSYRATS)
2. Stable on psychiatric medication for at least three months prior to the consent meeting
3. No plans for changes to psychiatric medication during the course of the study
4. Not received psychological therapy in the past three months or to have any plans for psychological therapy during the course of the study
5. Aged over 18 years of age
6. Able to provide informed consent to take part

Exclusion Criteria

1. Participants will not have an identified organic cause for their symptoms
2. Diagnosis of a learning disability.
3. Participants with a significant risk of violence to others.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Current primary outcome measures as of 24/05/2018:<br>1. Depression is measured using Beck Depression Inventory II (Beck et al, 1996) at baseline and 12 weeks<br>2. Psychotic symptoms are measured using the Psychotic Symptoms Rating Scale (PSYRATS): Delusions subscale at baseline and 12 weeks<br><br>Previous primary outcome measures:<br>1. Depression is measured using Beck Depression Inventory II (Beck et al, 1996) at baseline and 12 weeks<br>2. Recruitment rate is recorded as the number of participants consented to the study per research assistant days, measured at trial end<br>3. Retention rate is recorded as the number of participants contributing to all data collection points (providing full baseline and post-group data) at 12 weeks. The number of participants classified as completers (attended at least 6 mindfulness sessions) will also be reported

Secondary Outcome Measures

Name	Time	Method
Current secondary outcome measures as of 24/05/2018:<br>1. Recruitment rate is recorded as the number of participants consented to the study per research assistant days, measured at trial end.<br>2. Retention rate is recorded as the number of participants contributing to all data collection points (providing full baseline and post-group data) at 12 weeks. The number of participants classified as completers (attended at least 6 mindfulness sessions) will also be reported<br><br>Previous secondary outcome measures:<br>1. Quality of Life is measured using the World Health Organisation Quality of Life-Bref (WHOQOL-BREF) at baseline and 12 weeks<br>2. Psychotic symptoms are measured using the Psychotic Symptoms Rating Scale (PSYRATS): Delusions subscale at baseline and 12 weeks<br>3. Progress towards recovery is measured by The Choice of outcome in CBT for Psychosis (CHOICE) at baseline and 12 weeks